|
|
|
|
![WATCHMAN device](/legacy/block/afbeeldingen/WATCHMAN-device-006369-220x165px.png) | WATCHMAN device |
| ![AF Is Associated with Serious Events Different Vascular Territories1](/legacy/block/afbeeldingen/AF-Is-Associated-with-Serious-Events-Different-Vascular-Terr-006370-220x165px.png) | AF Is Associated with Serious Events Different Vascular Territories1 |
|
![Relative Risk Reduction of Stroke in Atrial Fibrillation](/legacy/block/afbeeldingen/Relative-Risk-Reduction-of-Stroke-in-Atrial-Fibrillation-006371-220x165px.png) | Relative Risk Reduction of Stroke in Atrial Fibrillation |
| ![Relative Risk Reduction of Stroke in Atrial Fibrillation](/legacy/block/afbeeldingen/Relative-Risk-Reduction-of-Stroke-in-Atrial-Fibrillation-006372-220x165px.png) | Relative Risk Reduction of Stroke in Atrial Fibrillation |
|
![Relative Risk Reduction of Stroke in Atrial Fibrillation](/legacy/block/afbeeldingen/Relative-Risk-Reduction-of-Stroke-in-Atrial-Fibrillation-006373-220x165px.png) | Relative Risk Reduction of Stroke in Atrial Fibrillation |
| ![AF Investigators’ Collaborative Analysis](/legacy/block/afbeeldingen/AF-Investigators-Collaborative-Analysis-006374-220x165px.png) | AF Investigators’ Collaborative Analysis |
|
![CHADS2 score](/legacy/block/afbeeldingen/CHADS2-score-006375-220x165px.png) | CHADS2 score |
| ![Dia 12](/legacy/block/afbeeldingen/Dia-12-006376-220x165px.png) | Dia 12 |
|
| ![Nieuwe antithrombotica bij boezemfibrilleren](/legacy/block/afbeeldingen/Nieuwe-antithrombotica-bij-boezemfibrilleren-006378-220x165px.png) | Nieuwe antithrombotica bij boezemfibrilleren |
|
![farmacologie](/legacy/block/afbeeldingen/farmacologie-006379-220x165px.png) | farmacologie |
|
|
| ![inclusion](/legacy/block/afbeeldingen/inclusion-006382-220x165px.png) | inclusion |
|
![exclusion](/legacy/block/afbeeldingen/exclusion-006383-220x165px.png) | exclusion |
|
|
![Dia 21](/legacy/block/afbeeldingen/Dia-21-006385-220x165px.png) | Dia 21 |
|
|
![Dia 23](/legacy/block/afbeeldingen/Dia-23-006387-220x165px.png) | Dia 23 |
|
|
![conclusions](/legacy/block/afbeeldingen/conclusions-006389-220x165px.png) | conclusions |
|
|
![RE-LY: A Non-inferiority Trial](/legacy/block/afbeeldingen/RE-LY-A-Non-inferiority-Trial-006391-220x165px.png) | RE-LY: A Non-inferiority Trial |
| ![RE-LY primary outcome: stroke or systemic embolism](/legacy/block/afbeeldingen/RE-LY-primary-outcome-stroke-or-systemic-embolism-006392-220x165px.png) | RE-LY primary outcome: stroke or systemic embolism |
|
![Stroke or Systemic Embolism](/legacy/block/afbeeldingen/Stroke-or-Systemic-Embolism-006393-220x165px.png) | Stroke or Systemic Embolism |
|
|
| ![RELY: Conclusions](/legacy/block/afbeeldingen/RELY-Conclusions-006396-220x165px.png) | RELY: Conclusions |
|
![Dia 33](/legacy/block/afbeeldingen/Dia-33-006397-220x165px.png) | Dia 33 |
| ![Study Design](/legacy/block/afbeeldingen/Study-Design-006398-220x165px.png) | Study Design |
|
![Primary Efficacy Outcome Stroke and non-CNS Embolism](/legacy/block/afbeeldingen/Primary-Efficacy-Outcome-Stroke-and-non-CNS-Embolism-006399-220x165px.png) | Primary Efficacy Outcome Stroke and non-CNS Embolism |
| ![ROCKET](/legacy/block/afbeeldingen/ROCKET-006400-220x165px.png) | ROCKET |
|
![ROCKET Summary](/legacy/block/afbeeldingen/ROCKET-Summary-006401-220x165px.png) | ROCKET Summary |
| ![RE-LY: A Non-inferiority Trial](/legacy/block/afbeeldingen/RE-LY-A-Non-inferiority-Trial-006402-220x165px.png) | RE-LY: A Non-inferiority Trial |
|
![RE-LY primary outcome: stroke or systemic embolism](/legacy/block/afbeeldingen/RE-LY-primary-outcome-stroke-or-systemic-embolism-006403-220x165px.png) | RE-LY primary outcome: stroke or systemic embolism |
| ![Stroke or Systemic Embolism](/legacy/block/afbeeldingen/Stroke-or-Systemic-Embolism-006404-220x165px.png) | Stroke or Systemic Embolism |
|
|
|
| ![Event rates in VKA group% per year)](/legacy/block/afbeeldingen/Event-rates-in-VKA-group-per-year-006408-220x165px.png) | Event rates in VKA group% per year) |
|
![A comparison of risk reductions; point estimates and CI’s](/legacy/block/afbeeldingen/A-comparison-of-risk-reductions-point-estimates-and-CI-s-006409-220x165px.png) | A comparison of risk reductions; point estimates and CI’s |
| ![conclusies](/legacy/block/afbeeldingen/conclusies-006410-220x165px.png) | conclusies |
|
![problemen](/legacy/block/afbeeldingen/problemen-006411-220x165px.png) | problemen |
| ![Gezondheidsraad 15 mei 2012](/legacy/block/afbeeldingen/Gezondheidsraad-15-mei-2012-006412-220x165px.png) | Gezondheidsraad 15 mei 2012 |
|
![Gezondheidsraad 15 mei 2012](/legacy/block/afbeeldingen/Gezondheidsraad-15-mei-2012-006413-220x165px.png) | Gezondheidsraad 15 mei 2012 |
|
Deel deze pagina met collega's en vrienden: